Annual report pursuant to Section 13 and 15(d)

Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)

v3.20.4
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)
12 Months Ended
Dec. 31, 2020
USD ($)
segment
reportingUnit
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Accounting Policies [Line Items]      
Number of operating segments | segment 2    
Advertising expense $ 300,000 $ 500,000 $ 500,000
Cash and cash equivalents 149,117,000 90,498,000 53,039,000
Cash 21,500,000 19,300,000  
Money market funds 127,600,000 71,200,000  
Current restricted cash 600,000 700,000  
Unbilled contracts receivable 10,900,000 10,100,000  
Impairment of long-lived assets held-for-use $ 0 0 0
Number of reporting units | reportingUnit 2    
Goodwill $ 3,241,000 3,241,000  
Goodwill impairment 0 0 0
Provision for (benefit from) income taxes 339,000 17,000 $ (37,000)
Novel Biotherapeutics      
Accounting Policies [Line Items]      
Goodwill $ 800,000    
Goodwill, allocation percent 24.00%    
Performance Enzymes      
Accounting Policies [Line Items]      
Goodwill $ 2,400,000    
Goodwill, allocation percent 76.00%    
Demand deposits | Letter of Credit      
Accounting Policies [Line Items]      
Cash deposit balance $ 1,100,000 $ 1,100,000